Hop­ing to chal­lenge block­buster breast can­cer fran­chis­es, a small Dutch biotech says its ADC passed a PhI­II test

For the last sev­er­al years, an un­der-the-radar chal­lenger to Big Phar­ma’s breast can­cer fran­chis­es has been work­ing on an an­ti­body drug con­ju­gate in­volv­ing Her­ceptin. On …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER